News | Digital Pathology | January 25, 2019

New Pathology Guideline Advances Accuracy in Breast Cancer Testing

Evidence-based guideline from College of American Pathologists helps labs use quantitative image analysis in HER2 immunohistochemistry testing

New Pathology Guideline Advances Accuracy in Breast Cancer Testing

January 25, 2019 — The College of American Pathologists (CAP) published the first-ever evidence-based clinical practice guideline to help laboratories use quantitative image analysis (QIA) in HER2 immunohistochemistry (IHC) testing for breast cancer. The guideline was published in an early online edition of the Archives of Pathology & Laboratory Medicine.1

QIA is the computer algorithm-assisted detection of specific features in an image following the digitalization of a glass slide image. Advancements in genomics, computing and imaging technology are spurring new opportunities to use QIA for diagnostic testing.  And while it has been shown to improve consistency and accuracy of interpretation compared to manual scoring by pathologists, the lack of a clinical guideline has been a barrier to wider QIA adoption.

"We set out to bridge the gap between technology and clinical practice with recommendations based on expert review of published literature," said project chair Marilyn M. Bui, M.D., Ph.D., FCAP, of the Moffitt Cancer Center, Tampa, Fla. "The recommendations will aid laboratories to ensure that diagnoses are accurate and consistent, which is essential to each patient's prognosis and treatment planning."

To develop the guideline, the CAP convened an expert panel of pathologists and histotechnologists with expertise in digital pathology, immunohistochemistry, quality management and breast pathology. The panel systematically reviewed more than 250 relevant articles and relied on evidence from more than 65 to develop the guideline's 11 recommendations. The guideline development process also included an open public comment period to include comments from professional associations and individuals, feedback from the guideline advisory panel, and independent peer review from a panel of CAP members.

Notably, the guideline recommends steps to validate QIA before implementing it, and steps for ongoing maintenance and evaluation so that quality is controlled and assured. Additionally, it recommends that laboratories should validate their QIA results for clinical use by comparing them to an alternative, validated method(s) such as HER2 in-situ hybridization methods or consensus images for HER2 IHC. The American Society for Clinical Pathology (ASCP) has endorsed the guideline through informed consideration by the ASCP Commission on Science, Technology & Policy.

The guideline is available at no charge on Additional resources including an instructional presentation and summary of the recommendations are also available.

For more information:

Related Digital Pathology Content

Roche Launches uPath Enterprise Digital Pathology Software


1. Bui M.M., Riben M.W., Allison K.H., et al. Quantitative Image Analysis of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry for Breast Cancer. Archives of Pathology & Laboratory Medicine. doi: 10.5858/arpa.2018-0378-CP

Related Content

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

Technology | Artificial Intelligence | July 18, 2019
Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded...
Johns Hopkins Named Qualified Provider-led Entity to Develop Criteria for Diagnostic Imaging
News | Clinical Decision Support | July 18, 2019
On June 30, 2019, the Centers for Medicare & Medicaid Services (CMS) announced the Johns Hopkins University School...
New Lung Ambition Alliance Aims to Double Five-year Lung Cancer Survival by 2025
News | Lung Cancer | July 17, 2019
The International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (...
Anatomage Releases Anatomage Cloud Platform
News | Remote Viewing Systems | July 16, 2019
Anatomage Inc. released an update to the Anatomage Cloud platform that allows medical and dental professionals to...
Graphic courtesy Pixabay

Graphic courtesy Pixabay

Feature | Artificial Intelligence | July 15, 2019 | By Greg Freiherr
Siemens has long focused on automation as a way to make diagnostic equipment faster and more efficient.
Videos | Artificial Intelligence | July 12, 2019
Khan Siddiqui, M.D., founder and CEO of HOPPR, discusses the economic advantages and costs presented by...
Videos | Digital Pathology | July 11, 2019
Toby Cornish, M.D., Ph.D., associate professor and medical director of informatics at the University of Colorado Scho
FDA Clears Koios DS Breast 2.0 AI-based Software
News | Ultrasound Women's Health | July 11, 2019
Koios Medical announced its second 510(k) clearance from the U.S. Food and Drug Administration (FDA).